MENIPREP Study: Evauation of the Effectiveness of Prp Injection in the Management of Degenerative… (NCT03866824) | Clinical Trial Compass
CompletedNot Applicable
MENIPREP Study: Evauation of the Effectiveness of Prp Injection in the Management of Degenerative Meniscal Lesions : Randomized Controlled Trial Double Blind Versus Reference Treatment"
France60 participantsStarted 2019-04-01
Plain-language summary
Meniscal tissue has very limited intrinsic properties in terms of repair, given the low mitotic activity of chondrocytes and poor vascularization. Nevertheless, its capacity for regeneration, in vivo and in vitro, can be stimulated by the contribution of growth factors, as has been widely described in the medical and scientific literature. Platelet Enhanced Plasma (PRP) is an autologous biological product (that is, derived from the patient's blood) containing a growth factor concentrate. The contribution of these growth factors stimulates cartilage repair by stimulating neovascularization, collagen synthesis and activation of chondrocytes. Intra-articular injection PRP is an autologous biological product, now used in daily practice for the treatment of early osteoarthritic lesions.
The hypothesis of this work is that the injection of PRP in contact with LMD(Degenerative Meniscal Lesions) will improve the clinical symptomatology of our patients compared to reference treatment (intra-auricular injection of corticosteroids).
Who can participate
Age range
20 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Men and women aged 20 to 80
* MDD diagnosis objected to MRI (grade II/III)
* Joint pain for more than 3 month
* Absence of bone lesion or moderate knee osteoarthritis stage \<2 on the Kellgren Laurence scale (objectified on radiography in schuss) in the 6 months prior to inclusion
* Axial deformity of the lower limbs less than or equal to 5 °
* Signed consent signed by the patient
* Ability to perform procedures as part of the follow-up (walk 50 steps on a flat surface and up / down stairs).
* Be affiliated to a health insurance scheme
Exclusion Criteria:
* Axial deformity\> 5 °
* Ligament instability
* Major injuries or surgery of the target knee or lateral contralateral knee in the 12 months preceding the inclusion visit
* Ligament reconstruction in the 12 months prior to the inclusion visit
* Need a cane or assistance to move
* BMI\> 35
* Thrombocytopenia \<150 G / L
* Thrombocytosis\> 450 G / L
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.